UY26424A1 - Método para tratar la diabetes - Google Patents

Método para tratar la diabetes

Info

Publication number
UY26424A1
UY26424A1 UY26424A UY26424A UY26424A1 UY 26424 A1 UY26424 A1 UY 26424A1 UY 26424 A UY26424 A UY 26424A UY 26424 A UY26424 A UY 26424A UY 26424 A1 UY26424 A1 UY 26424A1
Authority
UY
Uruguay
Prior art keywords
treating diabetes
post
prandial
diabetes
glyburide
Prior art date
Application number
UY26424A
Other languages
English (en)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26424A1 publication Critical patent/UY26424A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para tratamiento de diabetes del Tipo 2 empleando una combinación de metformina y gliburida. También se proporciona método para tratamiento de diabetes en pacientes sin experiencia en el fármaco empleando la formulación anterior para reducir la reducir la resistencia a la insulina y/o la excursión de la glucosa post-prandial y/o la hemoglobina 1Ac, y/o el incremento de la insulina post-prandial.
UY26424A 1999-11-03 2000-11-02 Método para tratar la diabetes UY26424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
UY26424A1 true UY26424A1 (es) 2001-05-31

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26424A UY26424A1 (es) 1999-11-03 2000-11-02 Método para tratar la diabetes

Country Status (23)

Country Link
EP (1) EP1229918B1 (es)
JP (1) JP5183844B2 (es)
KR (1) KR20070089259A (es)
CN (1) CN1450902A (es)
AR (1) AR026356A1 (es)
AT (1) ATE390140T1 (es)
AU (1) AU780106B2 (es)
BR (1) BR0015294A (es)
CA (1) CA2389928C (es)
EE (1) EE05260B1 (es)
HU (1) HU229352B1 (es)
IL (1) IL149139A0 (es)
LT (1) LT5058B (es)
LV (1) LV12910B (es)
MX (1) MXPA02004282A (es)
NO (1) NO330026B1 (es)
NZ (1) NZ518278A (es)
PL (1) PL199278B1 (es)
RU (1) RU2275915C2 (es)
SK (1) SK287810B6 (es)
TW (1) TWI280125B (es)
UY (1) UY26424A1 (es)
WO (1) WO2001032157A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
CN101897970A (zh) 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
BRPI0510613A (pt) * 2004-05-03 2007-10-30 Omega Bio Pharma Ip3 Ltd cisteaminas para tratar complicações de hipercolesterolemia e diabete
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
DK2200606T3 (en) 2007-09-10 2017-12-04 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT
WO2010043566A2 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem insulin und einem glp-1-agonisten
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US20120115799A1 (en) 2010-05-11 2012-05-10 Wenhua Wang Pharmaceutical formulations
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
CA2825162A1 (en) * 2011-02-02 2012-08-09 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
KR100666591B1 (ko) 1997-06-18 2007-01-11 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
SI0974356T1 (en) * 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
JP5183844B2 (ja) 2013-04-17
JP2003519621A (ja) 2003-06-24
MXPA02004282A (es) 2003-02-17
KR20070089259A (ko) 2007-08-30
WO2001032157A3 (en) 2002-01-24
EE05260B1 (et) 2010-02-15
HUP0300218A2 (hu) 2003-06-28
NO330026B1 (no) 2011-02-07
PL199278B1 (pl) 2008-09-30
NO20022087L (no) 2002-06-24
AU1082601A (en) 2001-05-14
SK287810B6 (sk) 2011-10-04
LV12910B (en) 2003-05-20
AU780106B2 (en) 2005-03-03
CA2389928C (en) 2010-03-23
LT2002063A (en) 2003-06-25
CA2389928A1 (en) 2001-05-10
WO2001032157A2 (en) 2001-05-10
RU2002114820A (ru) 2004-03-10
NO20022087D0 (no) 2002-05-02
EP1229918A2 (en) 2002-08-14
CN1450902A (zh) 2003-10-22
EE200200242A (et) 2003-12-15
AR026356A1 (es) 2003-02-05
IL149139A0 (en) 2002-11-10
EP1229918B1 (en) 2008-03-26
HUP0300218A3 (en) 2006-02-28
NZ518278A (en) 2004-10-29
ATE390140T1 (de) 2008-04-15
RU2275915C2 (ru) 2006-05-10
HU229352B1 (en) 2013-11-28
BR0015294A (pt) 2003-07-15
TWI280125B (en) 2007-05-01
SK5002002A3 (en) 2004-05-04
LT5058B (lt) 2003-09-25
PL364885A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
UY26424A1 (es) Método para tratar la diabetes
TNSN00206A1 (en) Method for treating diabetes
Groop et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans
ATE372782T1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
MXPA05006634A (es) Fluidos de dialisis biocompatibles que contienen icodextrinas.
PT88029A (pt) Processo para a preparacao de derivados piperazinilo de purinas e seus isoesteres uteis como agentes hipoglicemicos
ES2160581T3 (es) Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano.
ATE480256T1 (de) Plazentäre alkalische phosphatase zur diabeteskontrolle
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
NO920855L (no) Medikamentinneholdende matrise
CN205073517U (zh) 一种加速康复型心血管护理装置
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
Duhault et al. The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties. 2. Protective activity of S 1702 on the microvascular system in normal and diabetic rats
CN213311712U (zh) 一种心绞痛急救腕带储药装置
Papazafiropoulou et al. Diabetes drugs and cardiovascular safety
MX2021014997A (es) Agente de vanadio y metformina como principio activo para el tratamiento de padecimientos relacionados con la resistencia a la insulina.
Foy et al. Oral antihyperglycemic therapy for type 2 diabetes: Clinical applications
RU2000109897A (ru) Способ лечения диабетической нефропатии
Perez et al. Reductions of Alanine Transaminase Levels in Patients With Type 2 Diabetes Mellitus Treated With Pioglitazone Plus Sulfonylurea or Metformin
Lee Ask the doctor. I have diabetes and use insulin two, sometimes three, times a day to keep my sugar under control. My hope is that this will help me avoid a heart attack. Is this a reasonable goal?
Foy et al. Managing foot ulcers in patients with diabetes
Abbakumov et al. Use of sympathomimetic agents in the treatment of acute circulatory insufficiency in the immediate postoperative period of heart surgery patients

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20121123